Canopy Growth Powers European Expansion with UK Entry

SMITHS FALLS – Canopy Growth Corp. announced that it will supply four Canadian-grown medical Cannabis flower strains for distribution in the United Kingdom, expanding its international Cannabis business into another European market.

The products will be supplied to GROW Group U.K. Ltd., a British pharmaceutical company that imports, manufactures and distributes prescribed Cannabis-based medicines, and will be commercialized under Canopy’s Spectrum Therapeutics medical brand.

The flower originates from Canopy’s Kincardine, Ontario cultivation facility, which in August secured a renewed EU-GMP certification from German regulators – a central node in its European supply chain, connected to a second EU-GMP-certified facility in Sankt Leon-Rot, Germany. Despite Brexit, producers seeking a permit from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) still must meet EU-GMP standards, keeping Canopy’s existing certification relevant on both sides of the regulatory divide.

The UK is an unusual medical Cannabis market. Fewer than 20,000 National Health Service patients hold a Cannabis prescription, according to Cannabis Europa, leaving an estimated 100,000 patients receiving Cannabis through private clinics. That gap between public and private access is where Canopy, through GROW Group, is placing its first British bet.

The timing reflects genuine commercial momentum. Canopy’s international Cannabis revenue reached CA$8.6 million in the quarter ended June 30, 2026, up 10% year-over-year, with growth driven largely by European markets of Germany and Poland.

Canopy arrives in the UK with rivals already established. Aurora Cannabis acquired Internode Pharma and HAP Pharma in August, gaining a UK import facility and a licensed pharmacy. Tilray Brands has been selling branded flower through the Lyphe Clinic since August. Three Canadian producers are now competing for the same private-pay market through three different commercial channels.

Worth watching alongside this is a broader regulatory shift. German authorities issued guidance in June suggesting that Cannabis drying, a critical manufacturing step, should occur where Cannabis is harvested. If GMP obligations formally migrate upstream to the cultivation level, Canadian exporters across the continent could face additional scrutiny. The UK, now setting its own post-Brexit import standards, may or may not follow that course.

Canopy’s UK entry completes an important leg of its European buildout – one market at a time, behind a brand already present on the continent. How GROW Group performs as a commercial partner inside Britain’s clinic-heavy private market will ultimately say more about Canopy’s international outreach than any regulatory certification it holds.